Ausper Biopharma Co., Ltd.
Clinical trials sponsored by Ausper Biopharma Co., Ltd., explained in plain language.
-
New hope for hepatitis b: experimental drug aims to silence the virus
Disease control OngoingThis study tests an experimental drug called AHB-137 in adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral therapy. The goal is to see if adding AHB-137 can lower hepatitis B virus markers (HBsAg and HBV DNA) to undetectable levels. A…
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:58 UTC
-
New injection aims to silence hepatitis b virus in patients on standard therapy
Disease control OngoingThis study tests an experimental injection called AHB-137 in 20 adults with chronic hepatitis B who are already taking standard antiviral pills. The goal is to see if the injection can lower or eliminate hepatitis B surface antigen (HBsAg) and virus DNA in the blood, and improve …
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New shot aims to silence hepatitis b for good
Disease control OngoingThis study tests an experimental drug called AHB-137 in about 577 adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral pills. The goal is to see if adding AHB-137 injections can clear the hepatitis B surface antigen (HBsAg) from the blo…
Phase: PHASE3 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for hepatitis b: drug trial targets functional cure
Disease control OngoingThis study tests a new drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can lower the virus to undetectable levels and possibly achieve a functional cure, where the virus stays under control even after sto…
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:01 UTC